Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the ...

CRISPR Therapeutics' Q3 saw reduced expenses and slow Casgevy launch, resulting in a revenue miss. Read why I am neutral on ...

CRISPR Therapeutics ($CRSP) has endured a tough year since gaining several important regulatory approvals for its ...

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our ...

Thanks to the revolutionary advancements in CRISPR technology, medical specialists are on the verge of transforming how we ...

CRISPR Therapeutics (CRSP) presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and ...

Researchers in Lithuania present the molecular structure of a new, more-versatile CRISPR system for gene editing.

在一项新的研究中，斯坦福大学医学院的研究人员利用他们开发的基因筛选方法，发现了一种常用的化疗药物阿霉素（doxorubicin）会损害心脏细胞的原因，并找到了一种可能保护心脏细胞的药物。 相关研究结果于2024年11月7日在线发表在 Cell ...

作为RNA特异性靶向工具，CRISPR/Cas13技术提供了一种强大而有效的方法，这种精度对于揭示多种类型RNA在植物生长发育过程中的作用，如发育、应激反应等至关重要，这为植物功能研究和作物改良提供了新的技术手段。